These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 3299923

  • 1. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH, Vallera DA, Youle RJ, Haake R, Blazar BR, Arthur D, Neville DM, Ramsay NK, McGlave P, Kersey JH.
    Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
    [Abstract] [Full Text] [Related]

  • 2. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
    Filipovich AH, Vallera D, McGlave P, Polich D, Gajl-Peczalska K, Haake R, Lasky L, Blazar B, Ramsay NK, Kersey J.
    Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
    [Abstract] [Full Text] [Related]

  • 3. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 4. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 5. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S, Villa S, Bonadonna G, Bregni M, Gianni AM.
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [Abstract] [Full Text] [Related]

  • 6. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.
    Blood; 1999 Jul 15; 94(2):434-41. PubMed ID: 10397710
    [Abstract] [Full Text] [Related]

  • 7. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y.
    Int J Hematol; 1999 Jan 15; 69(1):27-35. PubMed ID: 10641440
    [Abstract] [Full Text] [Related]

  • 8. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 9. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
    Laurent G, Maraninchi D, Gluckman E, Vernant JP, Derocq JM, Gaspard MH, Rio B, Michalet M, Reiffers J, Dreyfus F.
    Bone Marrow Transplant; 1989 Jul 15; 4(4):367-71. PubMed ID: 2789084
    [Abstract] [Full Text] [Related]

  • 10. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH, Krawczak CL, Kersey JH, McGlave P, Ramsay NK, Goldman A, Goldstein G.
    Br J Haematol; 1985 May 15; 60(1):143-52. PubMed ID: 3890926
    [Abstract] [Full Text] [Related]

  • 11. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR, Ji SQ, Yan HM, Wang HX, Liu J, Xue M, Zhu L.
    Zhonghua Er Ke Za Zhi; 2004 Apr 15; 42(4):294-8. PubMed ID: 15157394
    [Abstract] [Full Text] [Related]

  • 12. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
    Neudorf SM, Rybka W, Ball E, Blatt J, Bloom E, Corey S, deMagalhaes-Silverman M, Koehler M, Lister J, Mierski J, Mirro J, Pincus S, Wilson J, Wollman M, Donnenberg AD.
    J Hematother; 1997 Aug 15; 6(4):351-9. PubMed ID: 9377073
    [Abstract] [Full Text] [Related]

  • 13. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease.
    Filipovich AH, Vallera DA, Youle RJ, Quinones RR, Neville DM, Kersey JH.
    Lancet; 1984 Mar 03; 1(8375):469-72. PubMed ID: 6142206
    [Abstract] [Full Text] [Related]

  • 14. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases.
    McGlave PB, Beatty P, Ash R, Hows JM.
    Blood; 1990 Apr 15; 75(8):1728-32. PubMed ID: 2328322
    [Abstract] [Full Text] [Related]

  • 15. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
    Cavazzana-Calvo M, André-Schmutz I, Hacein-Bey S, Schindler J, Vitetta H, Dupuis S, Quartier P, Chedeville G, Vilmer E, Casanova JL, Buffet R, Caillat-Zucman S, Radford I, Le Deist F, Fischer A.
    J Soc Biol; 2001 Apr 15; 195(1):65-8. PubMed ID: 11530503
    [Abstract] [Full Text] [Related]

  • 16. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB.
    Bone Marrow Transplant; 1995 Dec 15; 16(6):737-41. PubMed ID: 8750262
    [Abstract] [Full Text] [Related]

  • 17. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR.
    Blood; 1995 Nov 15; 86(10):3987-96. PubMed ID: 7579370
    [Abstract] [Full Text] [Related]

  • 18. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Mar 15; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 20. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F.
    Blood; 1994 Apr 01; 83(7):1980-7. PubMed ID: 8142664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.